Literature DB >> 11943185

Proteasome inhibitors prevent cytochrome c release during apoptosis but not in excitotoxic death of cerebellar granule neurons.

Antonella Bobba1, Nadia Canu, Anna Atlante, Vito Petragallo, Pietro Calissano, Ersilia Marra.   

Abstract

In order to find out whether and how proteasomes participate in the processes leading cerebellar granule cells to death either in necrosis, due to glutamate neurotoxicity, or in apoptosis, due to K(+) shift, we measured the three proteasome activities by using specific fluorescent probes and investigated the effect of several proteasome inhibitors, including MG132, on the cytochrome c release taking place in the early phase of both apoptosis and necrosis. We show that differently from apoptosis, the early phase of necrosis does not require proteasome activation. Inhibition of proteasome activity can prevent cytochrome c release in cerebellar granule cells undergoing apoptosis, thus improving cell survival, but not necrosis. These findings show that proteasomes play an important role in the early phase of apoptosis but not that of necrosis, and that these two types of cell death differ from each other in their mechanism of cytochrome c release.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11943185     DOI: 10.1016/s0014-5793(02)02231-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  Glutamate receptor activation evokes calpain-mediated degradation of Sp3 and Sp4, the prominent Sp-family transcription factors in neurons.

Authors:  Xianrong Mao; Shao-Hua Yang; James W Simpkins; Steven W Barger
Journal:  J Neurochem       Date:  2007-03       Impact factor: 5.372

2.  Trim17-mediated ubiquitination and degradation of Mcl-1 initiate apoptosis in neurons.

Authors:  M M Magiera; S Mora; B Mojsa; I Robbins; I Lassot; S Desagher
Journal:  Cell Death Differ       Date:  2012-09-14       Impact factor: 15.828

Review 3.  The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.

Authors:  Mario Di Napoli; BethAnn McLaughlin
Journal:  Curr Opin Investig Drugs       Date:  2005-07

4.  Cadmium induced p53-dependent activation of stress signaling, accumulation of ubiquitinated proteins, and apoptosis in mouse embryonic fibroblast cells.

Authors:  Xiaozhong Yu; Jaspreet S Sidhu; Sungwoo Hong; Joshua F Robinson; Rafael A Ponce; Elaine M Faustman
Journal:  Toxicol Sci       Date:  2011-01-20       Impact factor: 4.849

5.  Alzheimer's proteins, oxidative stress, and mitochondrial dysfunction interplay in a neuronal model of Alzheimer's disease.

Authors:  Antonella Bobba; Vito A Petragallo; Ersilia Marra; Anna Atlante
Journal:  Int J Alzheimers Dis       Date:  2010-09-02

6.  Systemic administration of proteasome inhibitor protects against MPTP neurotoxicity in mice.

Authors:  Takuya Oshikawa; Hayato Kuroiwa; Ryohei Yano; Hironori Yokoyama; Naoto Kadoguchi; Hiroyuki Kato; Tsutomu Araki
Journal:  Cell Mol Neurobiol       Date:  2009-04-16       Impact factor: 5.046

Review 7.  In vitro cultured neurons for molecular studies correlating apoptosis with events related to Alzheimer disease.

Authors:  Nadia Canu; Pietro Calissano
Journal:  Cerebellum       Date:  2003       Impact factor: 3.847

8.  Cadmium-induced activation of stress signaling pathways, disruption of ubiquitin-dependent protein degradation and apoptosis in primary rat Sertoli cell-gonocyte cocultures.

Authors:  Xiaozhong Yu; Sungwoo Hong; Elaine M Faustman
Journal:  Toxicol Sci       Date:  2008-05-06       Impact factor: 4.849

Review 9.  The role of the ubiquitin proteasome system in cerebellar development and medulloblastoma.

Authors:  Jerry Vriend; Saeid Ghavami; Hassan Marzban
Journal:  Mol Brain       Date:  2015-10-17       Impact factor: 4.041

Review 10.  Minocycline targets multiple secondary injury mechanisms in traumatic spinal cord injury.

Authors:  Robert B Shultz; Yinghui Zhong
Journal:  Neural Regen Res       Date:  2017-05       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.